Three-dimensional interactive heart models created with AI-enabled segmentation of CT scans may reduce ventricular tachycardia ablation procedure times by 60 percent.
The Food and Drug Administration (FDA) has granted 510(k) clearance for an artificial intelligence (AI)-enabled module from inHEART that delivers automated segmentation of preprocedural computed tomography (CT) scans that can create three-dimensional (3D) models of the heart.
Offering enhanced visualization of cardiac anatomy through the 3D models, the AI module can be seamlessly integrated into major electroanatomic mapping (EAM) systems, according to inHEART.
The company pointed out that early clinical evaluations of the AI module have shown a capability of reducing conventional ventricular tachycardia (VT) ablation procedures from five hours to less than two hours. inHeart added that image-guided procedures with the AI module’s 3D models may lead to a 38 percent reduction in VT recurrence rates.
"Our mission is to make world-class cardiac imaging expertise available to all physicians to optimize treatment strategies, improve clinical outcomes, and treat patients in a timely manner. With our new AI module, we look forward to scaling the production of inHEART's digital twin of the heart in more centers across the U.S.,” noted Todor Jeliaskov, the president and CEO of inHEART.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.